Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244725 · ClinicalTrials.gov registry record · Phase 2
Odiparcil For The Prevention Of Venous Thromboembolism
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 961
- Enrollment target
NCT00244725: Completed Phase 2 study, sponsored by GlaxoSmithKline.
NCT00244725 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 961 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (623% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00244725, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 961 participants
- Enrollment target
Study Summary
Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.
Primary Outcome
Participants were assessed for VTE at all study visits and at the end of study (Day 10±2) or at early withdrawal. Any participant who remained asymptomatic for VTE at the end of the study did not receive a mandatory bilateral venogram following at least 8 days on study medication. Participants who were withdrawn early and had been objectively confirmed to have a VTE event by a method other than venography were not required to undergo venography. A participant was included in the Independent Cent
Interventions
- DRUG Warfarin
- DRUG Coumadin
- DRUG Odiparcil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 961 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
What the finished NCT00244725 record still lists
NCT00244725 is an interventional study that assigns participants to a tested intervention. The registered 961 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (623% higher).
The record links to 0 conditions, and to 3 interventions - of which Warfarin is the first listed.
NCT00244725 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00244725 about?
NCT00244725 is a clinical study titled "Odiparcil For The Prevention Of Venous Thromboembolism". Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.
What is the current status of trial NCT00244725?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 961 participants. The study started on 2005-09. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00244725?
The interventions under investigation include: Warfarin (DRUG), Coumadin (DRUG), Odiparcil (DRUG).
Who is sponsoring clinical trial NCT00244725?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00244725's enrollment target sits among peer trials
961 28th of 2000 higher than 1,973 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04726241 · 960 participants · Phase 1
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- NCT05142384 · 960 participants · NA
ICBT (Internet Based Cognitive Behavioral Therapy) for Maternal Depression: Community Implementation in Head Start
- NCT05178498 · 960 participants
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
- NCT05946629 · 960 participants · NA
SELUTION 4 De Novo Small Vessel IDE Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia